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ABSTRACT 
Since human papillomavirus (HPV) infection was first identified as a risk factor for 
cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in 
relation to prostate cancer, another common genitourinary malignancy, with mixed results. To 
further inform this potential association, we conducted a large, prospective investigation of HPV 
types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial 
(PCPT). Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-
of-study biopsy (n=616). Controls were men not diagnosed with prostate cancer during the trial 
or on their end-of-study biopsy (n=616). Controls were frequency-matched to cases by age, 
treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG 
antibodies against HPV-16, -18 and -31. No associations were observed for weak or strong HPV-
16 (odds ratio (OR) = 0.94, 95% confidence interval (CI): 0.53-1.64, and OR=1.07, 95% CI: 
077-1.48, respectively), HPV-18 (OR=0.75, 95% CI: 0.27-2.04, and OR=0.87, 95% CI: 0.47-
1.63) or HPV-31 seropositivity (OR=0.76, 95% CI: 0.45-1.28, and OR=1.15, 95% CI: 0.80-1.64) 
and risk of prostate cancer. Considering this finding in the context of the HPV and prostate 
cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by 
mechanisms proposed to date, and using epidemiologic designs and laboratory techniques 
currently available.  
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INTRODUCTION 
Since human papillomavirus (HPV) infection was first identified as a risk factor for 
cervical cancer, several studies have investigated HPV in relation to prostate cancer with mixed 
results (1-7). When Taylor and colleagues (2) combined the results of ten of these studies, they 
observed a significant positive association between HPV and prostate cancer; however, 
subsequent investigations have observed null associations (3-6), or have detected minimal/no 
evidence of HPV in prostate tissue (7-12). To further inform HPV and prostate cancer, we 
conducted a prospective investigation of HPV types 16, 18, and 31 and prostate cancer in the 
Prostate Cancer Prevention Trial (PCPT, (13)). The unique design of this trial allowed us to 
investigate both HPV and screen-detected cancer among annually-screened men, as well as HPV 
and end-of-study biopsy-detected cancer to rule out differential likelihood of screening or biopsy 
as non-causal explanations for study findings.    
MATERIAL AND METHODS 
Study design 
We conducted a nested case-control study among PCPT participants with adequate serum 
at visit 2 (14). Cases were men with a confirmed diagnosis of prostate cancer after visit 2 
(n=616). Approximately equal numbers of cases diagnosed by “for-cause” and “end-of-study” 
biopsy were selected, as well as equal numbers with low- (Gleason sum <7) and high-grade (≥7) 
disease. The mean time from blood draw to diagnosis was 3.4 years for “for-cause” cases and 5.0 
for “end-of-study” cases. Controls were men not diagnosed with prostate cancer during the trial 
or on end-of-study biopsy (n=616). Controls were frequency-matched to cases by age, treatment 
arm, and family history of prostate cancer, and enriched for non-whites.  
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This study was approved by the Johns Hopkins Bloomberg School of Public Health and 
Fred Hutchinson Cancer Research Center Institutional Review Boards. 
HPV antibody assessment 
Sera were tested for IgG antibodies against HPV-16, -18 and -31 virus-like particles 
(VLPs) using enzyme-linked immunosorbent assays (ELISAs) specific for each HPV type (15). 
Samples were tested in random order, and laboratory personnel were blinded to case-control 
status. Each sample was tested in duplicate with repeat duplicate testing for duplicates with 
optical density (OD) coefficients of variation >25% and at least one value above the OD cut-off 
point for seropositivity. Mean OD values were calculated based on duplicate test values, or based 
on the mean of the three values in closest agreement for men with repeat duplicate testing. OD 
cut-off points of 0.080 (3 standard deviations (SDs) above the mean for control children), 0.100 
(3 SDs), and 0.065 (5 SDs) were initially used to define seropositivity for HPV-16, -18, and -31, 
respectively.  
Assay reproducibility was investigated by including 12 sets of ~6 blinded replicate 
samples each in the testing sequence (14). Eleven sets had 100% and one had 66.7% agreement 
for HPV-16; ten had 100% and two had 66.7% agreement for HPV-18; and ten had 100% and 
two had 83.3% agreement for HPV-31. Based on these data, we defined additional strong 
seropositive cut-off points to better distinguish likely seronegatives from seropositives (0.092 
(>4 SD), 0.117 (>4 SD) and 0.077 (>7 SD) for HPV-16, -18 and -31, respectively).   
Statistical analysis 
Age-, treatment arm-, family history-, and race-standardized OD means, geometric 
means, and proportions were calculated by prostate cancer status. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated by logistic regression adjusting for age, treatment arm, 
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family history, and race. Confounding was investigated by adding terms for ELISA plates, other 
HPV types, and other variables (14) individually to the model and comparing the results to the 
base model. Separate analyses were performed for prostate cancer diagnosed by for-cause and 
end-of-study biopsy, low- and high-grade cancer, organ-confined disease, and combinations 
thereof. Stratified analyses were performed to evaluate effect modification.  
A priori, we had ≥80% power to detect an OR≥1.6 for a control seroprevalence of 10%.  
RESULTS 
No differences were observed in the distribution of anti-HPV-16, -18 and -31 antibodies 
between cases and controls, or when the data for all three HPV types were combined (Tables 1 
and 2). Generally null results were also observed after adjustment for potential confounders, and 
for prostate cancer diagnosed by for-cause biopsy, Gleason sum <7 cancer, and organ-confined 
cancer. Very slight, non-significant positive findings were observed for HPV-16 and -31 with 
cancer diagnosed by end-of-study biopsy, and with Gleason sum ≥7 cancer (Table 2). No effect 
modification was observed by treatment arm, age at cancer diagnosis, family history of prostate 
cancer, or race. 
DISCUSSION 
In this large study of older American men, no associations were observed between HPV-
16, -18 and -31 and overall prostate cancer risk. Very slight, non-significant positive findings 
were observed for HPV-16 and -31 with prostate cancer diagnosed by end-of-study biopsy and 
Gleason sum ≥7 cancer, the reasons for which are unclear and could reflect chance findings. Our 
generally null results are consistent with those from most serologic studies conducted to date (3-
6, 16-20).  
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As in most previous serologic studies, we assessed HPV serostatus using VLP ELISAs 
and serum collected before but near cancer diagnosis, raising the possibility that antibody titers 
could have diminished since earlier “hit and run” infection(s), or during invasive cancer 
development. The former possibility was suggested by Strickler and Goedert (1) based on 
discrepancies between observed positive associations in studies that collected serum decades 
before diagnosis (21, 22), and null associations in studies that collected serum at diagnosis (16, 
17); while the latter was suggested by Rosenblatt and colleagues (20) based on stronger observed 
serologic associations for in situ than invasive HPV-associated cancers, which are likely closer in 
time to productive (capsid-expressing) HPV infections than invasive cancers. Since these studies 
were conducted, however, null results were observed in another study with early serum 
collection (3), and minimal/no evidence of HPV DNA was observed in most recent tissue-based 
studies (7-12), suggesting that waning capsid antibody titers are unlikely to explain null serologic 
results. 
Thus, viewing the HPV and prostate cancer literature as a whole, HPV does not appear to 
be associated with prostate cancer risk, at least by mechanisms proposed to date, and using 
epidemiologic designs and laboratory techniques currently available.   
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Table 1:  Human papillomavirus (HPV) types 16, 18 and 31 antibody distributions1 for 616 prostate 
cancer cases and 616 frequency-matched controls in the Prostate Cancer Prevention Trial  
  Cases2 Controls P-value3 
HPV-16    
Mean OD 0.06 0.06 0.60 
Geometric mean OD 0.05 0.05 0.56 
Serostatus (%):    
Seronegative (OD≤0.080) 81.3 81.8  
Weak seropositive (0.080<OD≤0.092) 4.1 4.5 0.90 
Strong seropositive (OD>0.092) 14.5 13.7  
HPV-18    
Mean OD 0.04 0.04 0.81 
Geometric mean OD 0.03 0.03 0.87 
Serostatus (%):    
Seronegative (OD≤0.100) 95.6 94.8  
Weak seropositive (0.100<OD≤0.117) 1.1 1.5 0.78 
Strong seropositive (OD>0.117) 3.3 3.7  
HPV-31    
Mean OD 0.05 0.05 0.48 
Geometric mean OD 0.04 0.04 0.48 
Serostatus (%):    
Seronegative (OD≤0.065) 83.5 83.6  
Weak seropositive (0.065<OD≤0.077) 4.3 5.6 0.41 
Strong seropositive (OD>0.077) 12.3 10.8  
HPV-16, -18 and/or -31    
All seronegative (%) 70.7 70.7  
At least one weak seropositive but no 
strong seropositives (%) 5.9 7.7  
One strong seropositive (%) 17.7 15.9 0.754 
Two strong seropositives (%) 4.6 4.8  
Three strong seropositives (%) 1.0 0.9  
At least one strong seropositive (%) 23.4 21.6 0.725 
OD=optical density  
1 Standardized by age, treatment arm, family history of prostate cancer and race (non-white versus white) using 
linear regression. 
2 Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study 
biopsy (1996-2003).  
3
 P-values were calculated by linear regression for continuous variables, and by generalized logit models for 
categorical variables. 
4
 P-value for the comparison of all seronegatives, at least one weak seropositive but no strong seropositives, one 
strong seropositive, two strong seropositives, and three strong seropositives. 
5
 P-value for the comparison of all seronegatives, at least one weak seropositive but no strong seropositives, and at 
least one strong seropositive. 
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Table 2:  Odds ratios (ORs) and 95% confidence intervals (CIs) of prostate cancer by human papillomavirus (HPV) type 16, 18 and 31 
serostatus in 616 prostate cancer cases1 and 616 frequency-matched controls in the Prostate Cancer Prevention Trial 
 HPV-16 HPV-18 HPV-31 
 Cases/controls OR2 (95% CI) Cases/controls OR2 (95% CI) Cases/controls OR2 (95% CI) 
Total prostate cancer:       
Seronegative3  503/502 1.00 590/583 1.00 516/513 1.00 
Weak seropositive4 25/28 0.94 (0.53-1.64) 7/9 0.75 (0.27, 2.04) 27/34 0.76 (0.45, 1.28) 
Strong seropositive5 88/86 1.07 (0.77-1.48) 19/24 0.87 (0.47, 1.63) 73/69 1.15 (0.80, 1.64) 
Prostate cancer diagnosed by for-cause biopsy3: 
Seronegative3  272/502 1.00 313/583 1.00 274/513 1.00 
Weak seropositive4 13/28 0.89 (0.45, 1.76) 6/9 1.21 (0.42, 3.45) 16/34 0.82 (0.44, 1.52) 
Strong seropositive5 42/86 0.92 (0.62, 1.37) 8/24 0.69 (0.31, 1.58) 37/69 1.05 (0.68, 1.62) 
Prostate cancer diagnosed by end-of-study biopsy4: 
Seronegative3  231/502 1.00 277/583 1.00 242/513 1.00 
Weak seropositive4 12/28 1.01 (0.50, 2.06) 1/9 0.22 (0.03, 1.72) 11/34 0.65 (0.32, 1.31) 
Strong seropositive5 46/86 1.25 (0.84, 1.86) 11/24 1.08 (0.51, 2.28) 36/69 1.27 (0.82, 1.99) 
Gleason sum <7 prostate cancer: 
Seronegative3  261/502 1.00 299/583 1.00 269/513 1.00 
Weak seropositive4 16/28 1.24 (0.65, 2.38) 5/9 1.11 (0.36, 3.42) 14/34 0.72 (0.38, 1.38) 
Strong seropositive5 36/86 0.82 (0.54, 1.26) 9/24 0.83 (0.37, 1.86) 30/69 0.94 (0.59, 1.50) 
Gleason sum ≥7 prostate cancer: 
Seronegative3  242/502 1.00 291/583 1.00 247/513 1.00 
Weak seropositive4 9/28 0.69 (0.32, 1.49) 2/9 0.41 (0.09, 1.91) 13/34 0.77 (0.40, 1.49) 
Strong seropositive5 52/86 1.31 (0.89, 1.91) 10/24 0.90 (0.42, 1.92) 43/69 1.33 (0.88, 2.03) 
Organ-confined (≤T2N0M0) prostate cancer: 
Seronegative3  459/502 1.00 540/583 1.00 473/513 1.00 
Weak seropositive4 24/28 0.98 (0.56, 1.74) 7/9 0.83 (0.30, 2.25) 26/34 0.79 (0.47, 1.35) 
Strong seropositive5 83/86 1.10 (0.79, 1.53) 19/24 0.95 (0.51, 1.77) 67/69 1.16 (0.80, 1.67) 
1 
 Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (1996-2003). 
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2
 Calculated by unconditional logistic regression, including terms for age (continuous), treatment arm, family history of prostate cancer and non-white race. 
3
 HPV-16: OD≤0.080; HPV-18: OD≤0.100; HPV-31: OD≤0.065. 
4
 HPV-16: 0.080<OD≤0.092; HPV-18: 0.100<OD≤0.117; HPV-31: 0.065<OD≤0.077. 
5
 HPV-16: OD>0.092; HPV-18: OD>0.117; HPV-31: OD>0.077. 
6
 Refers to a biopsy performed because of an elevated prostate specific antigen concentration or an abnormal digital rectal examination. 
7
 Refers to a biopsy performed without indication after seven years of participation in the study as part of the study protocol. 
